Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDICI study of obicetrapib versus bempedoic acid in high-risk dyslipidemia
2025-524265-24-00Phase 3Authorised
- Sponsor
- Menarini Group
- Start
- May 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia, hypercholesterolemia and combined dyslipidaemia comparing Obicetrapib arm with Bempedoic acid arm (2 arms). Primary endpoint: Percentage change in LDL-C from baseline to Day 84. Planned start May 2026; status: authorised.
02
Drugs
obicetrapibbempedoic acid
03
Conditions
dyslipidemiahypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2025-524265-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524265-24-00.